Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 8-9, Août-Septembre 2003
Page(s) 819 - 825
Section M/S Revues
Publié en ligne 15 août 2003
  1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–81.
  2. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002; 90: 55i–61i.
  3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–35.
  4. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717–26.
  5. Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR alpha activators. J Biol Chem 2003; 278: 17982–5.
  6. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SRBI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferatoractivated receptors. Circulation 2000; 101: 2411–7.
  7. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53–8.
  8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs highdensity lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410–8.
  9. DAIS-group. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001; 357: 905–10.
  10. BIP group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–7.
  11. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779–85.
  12. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–3.
  13. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137–45.
  14. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122–8.
  15. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305–7.
  16. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042–7.
  17. Holst D, Grimaldi PA. New factors in the regulation of adipose differentiation and metabolism. Curr Opin Lipidol 2002; 13: 241–5.
  18. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376–80.
  19. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferatoractivated receptor- gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539–47.
  20. Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor gamma agonists. J Clin Invest 2000; 106: 467–72.
  21. Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferatoractivated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14: 1425–33.
  22. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferatoractivated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102–6.
  23. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferatoractivated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002; 16: 2628–44.
  24. Lohray BB, Lohray VB, Bajji AC, et al. (-)3-[4-[2- (Phenoxazin-10- yl)ethoxy]phenyl]-2- ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001; 44: 2675–8.
  25. Etgen GJ, Oldham BA, Johnson WT, et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002; 51: 1083–7.
  26. Vikramadithyan RK, Hiriyan J, Gershome C, Rajagopalan R, Chahrabarti R. Biochemical effects of the dual PPARalpha and gamma agonist ragaglitazar on glucose and lipid metabolism. San Francisco: American Diabetes Association, 2002: abstract 584–P.
  27. Ide T, Nakazawa T, Mochizuki T, Murakami K. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 2000; 49: 521–5.
  28. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and - gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000; 130: 495–504.
  29. Ye JM, Iglesias MA, Watson DG, et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284: E531–40.
  30. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998; 47: 1841–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.